rss Posted December 31, 2008 Report Share Posted December 31, 2008 Related Articles [Are there any clinical evaluations confirming higher incidence of skin cancers as a result of pimecrolimus therapy?] Pol Merkur Lekarski. 2008 Sep;25(147):284-7 Authors: Barańjska-Rybak W, Nowicki R, Sokołowska-Wojdyło M, Roszkiewicz J Pimecrolimus (SDZ ASM 981), nonsteroid anty-inflammatory ackomycin-derived drug has more and more indications in dermatology. It has been recommended in therapy of atopic and contact dermatitis at the beginning. Nowadays pimecrolimus is used in the treatment of seborrhoic dermatitis, post-steroidal rosacea, bullous diseases etc. News reporting higher incidence of skin cancers after pimecrolimus application has not been proved clinically. The common use of mentioned medication forced us to detailed analysis of references concerning that problem. PMID: 19112851 [PubMed - in process] http://www.ncbi.nlm.nih.gov/entrez/query.f...p;dopt=Abstract = URL to article Link to comment Share on other sites More sharing options...
Recommended Posts
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now